Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ALDX NASDAQ:PBYI NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.48+2.1%$1.38$1.14▼$4.08$397.01M0.352.99 million shs3.99 million shsALDXAldeyra Therapeutics$1.74+1.2%$2.75$1.07▼$6.18$104.96M1.162.45 million shs1.15 million shsPBYIPuma Biotechnology$7.45+1.4%$6.81$2.85▼$7.90$379.13M1.24373,980 shs484,456 shsXFORX4 Pharmaceuticals$4.38+4.3%$3.99$1.35▼$4.83$398.23M0.31455,540 shs651,440 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+3.57%+2.11%+5.07%+5.84%-38.03%ALDXAldeyra Therapeutics+8.18%+9.55%+3.61%-67.05%-36.30%PBYIPuma Biotechnology-1.87%-2.52%+6.52%+3.52%+139.41%XFORX4 Pharmaceuticals+0.24%+1.94%-0.94%+9.09%+27.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.48+2.1%$1.38$1.14▼$4.08$397.01M0.352.99 million shs3.99 million shsALDXAldeyra Therapeutics$1.74+1.2%$2.75$1.07▼$6.18$104.96M1.162.45 million shs1.15 million shsPBYIPuma Biotechnology$7.45+1.4%$6.81$2.85▼$7.90$379.13M1.24373,980 shs484,456 shsXFORX4 Pharmaceuticals$4.38+4.3%$3.99$1.35▼$4.83$398.23M0.31455,540 shs651,440 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+3.57%+2.11%+5.07%+5.84%-38.03%ALDXAldeyra Therapeutics+8.18%+9.55%+3.61%-67.05%-36.30%PBYIPuma Biotechnology-1.87%-2.52%+6.52%+3.52%+139.41%XFORX4 Pharmaceuticals+0.24%+1.94%-0.94%+9.09%+27.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.40Hold$4.67214.25% UpsideALDXAldeyra Therapeutics 2.00Hold$5.50211.61% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/AXFORX4 Pharmaceuticals 2.40Hold$8.5096.76% UpsideCurrent Analyst Ratings BreakdownLatest ALDX, PBYI, XFOR, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/27/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/9/2026XFORX4 Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.002/26/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell2/25/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.002/6/2026AKBAAkebia Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $4.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.69N/AN/A$0.12 per share12.38ALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/APBYIPuma Biotechnology$228.40M1.70$0.84 per share9.03$2.59 per share2.94XFORX4 Pharmaceuticals$35.11M11.19N/AN/A$2.13 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.02N/AN/AN/A-2.26%-16.70%-1.53%5/7/2026 (Estimated)ALDXAldeyra Therapeutics-$33.85M-$0.57N/AN/AN/AN/A-63.75%-41.27%5/13/2026 (Estimated)PBYIPuma Biotechnology$31.11M$0.6112.4922.38N/A13.62%27.80%15.35%5/7/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.34N/AN/AN/A-225.55%-115.27%-45.97%5/6/2026 (Estimated)Latest ALDX, PBYI, XFOR, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALDXAldeyra Therapeutics-$0.13N/AN/AN/AN/AN/A5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01N/AN/AN/A$51.67 millionN/A5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13N/AN/AN/A$42.00 millionN/A5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 million3/17/2026Q4 2025XFORX4 Pharmaceuticals-$0.36-$0.22+$0.14$1.00$1.68 million$2.57 million2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/A2/26/2026Q4 2025AKBAAkebia Therapeutics-$0.03-$0.05-$0.02-$0.05$48.37 million$57.62 million2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALDXAldeyra TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.481.551.46ALDXAldeyra TherapeuticsN/A2.582.58PBYIPuma BiotechnologyN/A2.001.93XFORX4 Pharmaceuticals0.4110.169.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALDXAldeyra Therapeutics59.71%PBYIPuma Biotechnology61.29%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ALDXAldeyra Therapeutics8.50%PBYIPuma Biotechnology23.30%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.25 million260.20 millionOptionableALDXAldeyra Therapeutics1060.32 million55.19 millionOptionablePBYIPuma Biotechnology20050.89 million39.03 millionOptionableXFORX4 Pharmaceuticals8090.92 million89.89 millionNo DataALDX, PBYI, XFOR, and AKBA HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results2 hours ago | marketbeat.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6 at 9:31 AM | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6 at 7:31 AM | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6 at 7:15 AM | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of "Hold" from BrokeragesApril 16, 2026 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Trading Up 0.7% - Time to Buy?April 14, 2026 | marketbeat.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90March 27, 2026 | msn.comX4 Jumps on Q4 FiguresMarch 17, 2026 | baystreet.caX4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesMarch 17, 2026 | zacks.comX4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment ProgressMarch 17, 2026 | quiverquant.comQX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 17, 2026 | globenewswire.comGuggenheim initiates coverage of X4 Pharmaceuticals (XFOR) with buy recommendationMarch 10, 2026 | msn.comX4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst AttentionMarch 9, 2026 | 247wallst.comX4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceMarch 4, 2026 | globenewswire.comX4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA ApprovalMarch 3, 2026 | seekingalpha.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comX4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeFebruary 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALDX, PBYI, XFOR, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$1.48 +0.03 (+2.07%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.01 (-1.01%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Aldeyra Therapeutics NASDAQ:ALDX$1.74 +0.02 (+1.16%) Closing price 04:00 PM EasternExtended Trading$1.71 -0.03 (-1.61%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Puma Biotechnology NASDAQ:PBYI$7.45 +0.10 (+1.36%) Closing price 04:00 PM EasternExtended Trading$7.46 +0.00 (+0.07%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.X4 Pharmaceuticals NASDAQ:XFOR$4.38 +0.18 (+4.29%) Closing price 04:00 PM EasternExtended Trading$4.37 -0.01 (-0.23%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
